Over the last 50 years, the shift to value-based medicine has been driven by regulatory bodies to bring about a remarkable confluence of real-world data (RWD) and technology acceleration at pharmaceutical companies. One of the most exciting developments is the number of potential use cases for the application of integrated real-world data across the oncology drug development lifecycle.
Given the rapid pace of innovation, expansion, and adoption; real-world data can no longer be a series of static, one-time purchases. Rather, the new paradigm of insight and real-world evidence (RWE) generation is lifelong and enterprise-level and requires a living dataset that can grow and evolve with the needs of researchers and the patients they serve.
Join Warren Whyte, PhD, Vice President of Scientific Partnerships and Customer Success at ConcertAI, for a live webinar on how “living” datasets work and how such advanced oncology RWD can accelerate an enterprise-level approach to RWE.
“Living” RWD for Enterprise Evidence Generation: Creating a 360-degree View of the Patient
What You Will Learn
- Use cases supported by a modern-day dataset.
- Most impactful use cases for today – and the future.
- Key considerations when evaluating datasets for regulatory-grade clinical research.
- Importance of deep biomarker data spanning multiple tumor types.
- On-demand access to deeply abstracted variables and reducing time to evidence generation for regulatory submission.
Who Should Attend
Professionals who are involved in:
- Clinical Development
- Clinical Operations
- Translational Medicine
- Medical Affairs
- HEOR/Epi Scientists
- RWE Center of Excellence
About the Speaker
Warren Whyte, PhD, VP Scientific Partnerships & Customer Success
Dr. Whyte is focused on advancing ConcertAI’s partnerships with life sciences and healthcare customers in delivering truly innovative data and AI-powered medicines to patients.
His experience includes several years at Accenture, where he led the strategic delivery of RWE offerings for leading drug and medical device companies across medical affairs, R&D and commercial functions. Prior to Accenture, Dr. Whyte consulted for several biopharmaceutical companies, and led research in genomics and molecular biology that preceded the creation of Syros Pharmaceuticals, a venture-backed gene therapy company. Dr. Whyte has published in several peer-reviewed scientific journals. He has a BS in molecular and cell biology from Cornell University and a PhD in genomics from MIT.